| Literature DB >> 26254614 |
Yihua Wu1,2, Wei Lu3, Jinming Xu3, Yu Shi4, Honghe Zhang5, Dajing Xia6.
Abstract
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) was identified to be the first long non-coding RNA as a biomarker of independent prognostic value for early stage non-small cell lung cancer patient survival. In recent years, the association between upregulated tissue MALAT1 level and incidence of various cancers including bladder cancer, colorectal cancer, and renal cancer has been widely discussed. The aim of our present study was to assess the potential prognostic value of MALAT1 in various human cancers. PubMed, Embase, Ovid, and Cochrane Library databases were systematically searched, and eligible studies evaluating the prognostic value of MALAT1 in various cancers were included. Finally, 11 studies encompassing 1216 participants reporting with sufficient data were enrolled in the current meta-analysis. The pooled hazard ratio (HR) was 2.05 (95 % confidence interval (CI) 1.64-2.55, p < 0.01) for overall survival (OS) and 2.66 (95 % CI 1.86-3.80, p < 0.01) for disease-free survival (DFS). In conclusion, high tissue MALAT1 level was associated with an inferior clinical outcome in various cancers, suggesting that MALAT1 might serve as a potential prognostic biomarker for various cancers.Entities:
Keywords: Cancer; Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1); Prognostic value
Mesh：
Substances：
Year: 2015 PMID： 26254614 DOI： 10.1007/s13277-015-3870-8
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283